Interchangeability, Adverse Event Considerations for Adalimu

Patients who switched from originator adalimumab to a biosimilar experienced more treatment-emergent adverse events compared to those who stuck with the biosimilar or the reference drug.

Related Keywords

Spain , Grenada , Eduardo Redondo Cerezo , Linkedin Eduardo Redondo Cerezo , University Of Grenada , Virgen De Las Nieves University Hospital , Ibd , Inflammatory Bowel Disease , Ulcerative Colitis , Crohn X27s Disease , Persistence , Adalimumab , Biosimilar ,